EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage…
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
June 14, 2025 10:48 ET Â | Source: Celldex Therapeutics, Inc. 77% of…
Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting…
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
- The Company is developing an enhanced immunosuppressive regimen in consultation with…
GT Biopharma Appoints New Member to its Board of Directors
SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc.…
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the…
Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing
1st production of pharmaceutical grade egg and milk challenge mealsProduct portfolio of…
EyeCare Partners Releases Inaugural Quality and Outcomes Report, Showcasing Impact and Industry-Leading Benchmarks
ST. LOUIS--(BUSINESS WIRE)--EyeCare Partners (ECP), the nation’s leading provider of clinically integrated…
Wysa Launches AI-Powered Chatbot to Streamline Mental Health Patient Intake in the US
Automated screening cuts patient assessment time by 30 minutes in real-world useBOSTON--(BUSINESS…